Centene Corporation CNC SPXR3KPHARMA

Q: What is the current share price of Centene Corporation (CNC)?

As of 2026-09-07 16:24 PDT, Centene Corporation (CNC) trades at $67.04 on NYSE. Its 52-week range is $26.93 to $68.72.

Q: What is the market capitalisation of CNC?

Centene Corporation (CNC) has a market capitalisation of $33.12B on NYSE.

Q: What is the P/E ratio of CNC?

CNC trades at a trailing price-to-earnings (P/E) ratio of -6.47. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.44.

Q: What is the return on equity (ROE) of CNC?

CNC has a return on equity (ROE) of -20.36%. Its return on capital employed (ROCE) is -19.03%.

Q: Is CNC a good stock to buy?

This page provides a data-driven analysis of Centene Corporation (CNC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Healthcare Plans · United States

https://www.centene.com

Company Profile ↓

$67.04

+147.65% 1Y

Mkt Cap$33.12B

P/E-6.47

P/B1.44

52W High$68.72

52W Low$26.93

Book Value$45.67

EPS (TTM)$-10.36

Company Overview

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 26.2% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $174.58B (+20.0% YoY); net profit $-6.67B.
Trailing 12 Months Year-on-year growth — revenue +4.6%, earnings -301.9%.
5-Year Trend Long-term compounding — revenue CAGR 26.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	26.15%
1 Year:	4.60%

Compounded Profit Growth

5 Years:	-
1 Year:	-301.94%

Stock Price Performance

1 Year:	+147.65%
6 Months:	+53.59%
3 Months:	+7.56%
1 Month:	+4.42%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 96% of range

$26.93 $68.72

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)55.67 · Neutral

Price Performance

1M+4.42%

3M+7.56%

6M+53.59%

1Y+147.65%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 26.2% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-6.47

Industry PE

25.17

Forward P/E

12.78

PEG Ratio

1.13

Book Value

$45.67

Price to Book

1.44

P/S

0.18

EV/EBITDA

4.70

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

26.15%

Profit 5Y

Revenue (YoY)

4.60%

Earnings (YoY)

-301.94%

Profitability & Returns

ROCE

-19.03%

ROE

-20.36%

ROA

2.48%

Profit Margin

-2.83%

Op Margin

3.76%

Gross Margin

11.42%

EPS (Latest Qtr)

$2.19

EPS (TTM)

$-10.36

Balance Sheet & Liquidity

Debt/Equity

0.71

Quick Ratio

1.11

Current Ratio

1.15

Debt

$16.10B

Total Assets

$83.01B

Current Assets

Working Capital

Ownership

Promoter Holding

0.38%

Chg in Prom Hold

-0.01%

FII / Inst Holding

101.42%

Chg in FII Hold

0.05%

Financial Snapshot

Enterprise Value

$33.12B

Total Revenue (TTM)

$180.30B

EBITDA

$4.61B

Free Cash Flow

$9.64B

Operating Cash Flow

$9.75B

Shares Outstanding

494.00M

Gross Margin

11.42%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CNC Centene Corporation SPXR3KPHARMA	67.04	-6.47	$33.12B	0.00%	-19.03%	-20.36%	26.15%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	11.44B	11.42B	-	12.56B	12.88B	15.36B	-	16.84B	17.30B	18.21B	-	24.17B	25.72B	27.46B	28.11B	28.86B	30.51B	34.23B	33.97B	33.73B	34.95B	34.84B	34.97B	36.34B	35.97B	36.90B	42.49B	42.47B	44.90B	44.66B	44.38B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.41B	4.56B	4.04B	4.65B	4.61B	4.63B	4.74B	4.53B	4.01B	5.29B	3.02B	3.35B	5.65B	4.62B
Operating Income	129.00M	173.00M	183.00M	-	20.00M	377.00M	342.00M	-	240.00M	438.00M	340.00M	-	540.00M	489.00M	41.00M	-	685.00M	643.00M	176.00M	-	188.00M	2.02B	861.00M	1.05B	-418.00M	545.00M	1.25B	-129.00M	476.00M	1.22B	1.17B	735.00M	1.11B	1.23B	665.00M	1.53B	-458.00M	-6.95B	1.86B	1.20B
Net Income	63.00M	88.00M	93.00M	111.00M	-16.00M	170.00M	147.00M	261.00M	139.00M	254.00M	205.00M	230.00M	340.00M	300.00M	19.00M	241.00M	522.00M	495.00M	95.00M	209.00M	46.00M	1.21B	568.00M	699.00M	-535.00M	584.00M	849.00M	-172.00M	738.00M	1.13B	1.06B	469.00M	1.16B	1.15B	713.00M	1.31B	-253.00M	-6.63B	1.54B	1.09B
Diluted EPS	0.51	0.72	0.76	0.90	-0.13	0.97	0.84	1.49	0.39	0.72	0.58	0.65	0.96	0.75	0.05	0.57	1.24	1.18	0.23	0.49	0.08	2.05	0.97	1.19	-0.92	0.99	1.44	-0.29	1.27	2.04	1.92	0.87	2.16	2.16	1.36	2.63	-0.51	-13.50	3.11	2.19

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	3.36B	4.10B	4.45B	5.21B	8.11B	10.86B	16.56B	22.76B	37.58B	45.62B	56.44B	70.36B	103.80B	117.98B	135.48B	140.09B	145.50B	174.58B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	14.49B	16.92B	17.64B	17.07B	14.21B
Operating Income	131.56M	138.13M	157.07M	203.80M	108.00M	277.00M	464.00M	705.00M	1.26B	1.20B	1.46B	1.78B	3.08B	1.78B	1.32B	2.93B	3.17B	-7.62B
Net Income	83.50M	83.67M	94.84M	111.22M	2.00M	165.00M	271.00M	355.00M	562.00M	828.00M	900.00M	1.32B	1.81B	1.35B	1.20B	2.70B	3.31B	-6.67B
Diluted EPS	1.88	1.89	1.88	2.12	0.02	1.47	2.25	2.88	1.71	2.34	2.26	3.14	3.12	2.28	2.07	4.95	6.31	-13.53

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.70B	1.94B	2.19B	2.77B	3.52B	5.82B	7.34B	20.20B	21.86B	30.90B	40.99B	68.72B	78.38B	76.87B	84.64B	82.44B	76.75B
Total Equity	415.05M	501.27M	600.85M	793.94M	935.63M	953.06M	1.23B	1.74B	2.16B	5.89B	6.85B	10.92B	12.55B	25.77B	26.80B	24.06B	25.84B	26.41B	19.95B
Cash & Equivalents	268.58M	379.10M	403.75M	434.17M	573.70M	745.93M	974.00M	1.61B	1.76B	3.93B	4.07B	5.34B	12.12B	10.80B	13.12B	12.07B	17.19B	14.06B	17.89B
Long Term Debt	-	-	307.08M	327.82M	348.34M	535.48M	666.00M	874.00M	1.22B	4.65B	4.70B	6.65B	13.64B	16.68B	18.57B	17.94B	17.71B	18.42B	17.35B
Total Liabilities	-	-	1.08B	1.15B	1.25B	1.82B	2.29B	3.93B	5.01B	14.14B	14.98B	19.88B	28.30B	42.76B	51.35B	52.63B	58.69B	55.94B	56.69B
Current Liabilities	-	-	715.91M	765.25M	837.61M	1.23B	1.56B	2.90B	3.63B	8.62B	9.33B	11.97B	12.93B	21.59B	25.77B	28.46B	36.72B	34.26B	36.70B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	221.98M	248.19M	168.93M	261.70M	279.00M	382.00M	1.22B	658.00M	1.85B	1.49B	1.23B	1.48B	5.50B	4.21B	6.26B	8.05B	154.00M	5.09B
Investing Cash Flow	-153.92M	-270.09M	-210.61M	-129.08M	-188.00M	-342.00M	-848.00M	-813.00M	-2.47B	-1.25B	-4.58B	-1.53B	-6.96B	-3.30B	-2.92B	-1.19B	-1.05B	472.00M
Financing Cash Flow	42.46M	46.55M	72.09M	6.91M	179.00M	154.00M	198.00M	305.00M	2.72B	-82.00M	4.61B	6.83B	260.00M	1.36B	-4.20B	-1.66B	-2.41B	-1.62B
Capital Expenditure	-65.16M	-23.72M	-118.56M	-73.71M	-82.00M	-68.00M	-103.00M	-150.00M	-306.00M	-422.00M	-675.00M	-730.00M	-869.00M	-910.00M	-1.00B	-799.00M	-644.00M	-767.00M
Free Cash Flow	156.82M	224.47M	50.38M	187.99M	197.00M	314.00M	1.12B	508.00M	1.54B	1.07B	559.00M	753.00M	4.63B	3.29B	5.26B	7.25B	-490.00M	4.32B
Share Buybacks	23.51M	6.30M	3.22M	7.81M	13.00M	19.00M	29.00M	53.00M	63.00M	65.00M	71.00M	75.00M	626.00M	297.00M	3.10B	1.63B	3.12B	475.00M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	12.3%	12.5%	12.6%	11.7%	8.1%
Operating Margin %	3.9%	3.4%	3.5%	3.9%	1.3%	2.5%	2.8%	3.1%	3.4%	2.6%	2.6%	2.5%	3.0%	1.5%	1.0%	2.1%	2.2%	-4.4%
Net Margin %	2.5%	2.0%	2.1%	2.1%	0.0%	1.5%	1.6%	1.6%	1.5%	1.8%	1.6%	1.9%	1.7%	1.1%	0.9%	1.9%	2.3%	-3.8%
ROE %	16.7%	13.9%	11.9%	11.9%	0.2%	13.4%	15.5%	16.5%	9.5%	12.1%	8.2%	10.5%	7.0%	5.0%	5.0%	10.5%	12.5%	-33.4%
ROCE %	-	14.0%	13.3%	15.1%	7.0%	14.1%	15.9%	19.0%	10.9%	9.6%	7.7%	6.3%	6.5%	3.4%	2.7%	6.1%	6.6%	-19.0%

Shareholding Pattern

Insiders

0.38%

Institutions

101.42%

Public Float

101.81%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.39%	41.45M	$2.68B
2	Vanguard Capital Management LLC	6.37%	31.48M	$2.04B
3	AQR Capital Management, LLC	5.81%	28.68M	$1.86B
4	Vanguard Portfolio Management LLC	4.52%	22.35M	$1.45B
5	State Street Corporation	4.45%	21.97M	$1.42B
6	Geode Capital Management, LLC	2.69%	13.31M	$861.80M
7	Wellington Management Group, LLP	2.69%	13.30M	$861.25M
8	Ameriprise Financial, Inc.	2.51%	12.42M	$804.16M
9	Invesco Ltd.	2.26%	11.18M	$723.89M
10	Harris Associates L.P.	2.25%	11.12M	$720.32M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CNC

Google News Fri, 04 Sep 2026

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTE52WWFuZW80X1N5Vnh3dnZxN19HNzlTZkxkS2xmMnpTVkJCc1FMUUozOFE4Zmd1MkFiOW9WalNvLUhtNVZOaEwyS0k3YTlXaTQ?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>  <font…

Google News Wed, 02 Sep 2026

Is Centene (CNC) a Great Value Stock Right Now? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOeDNzSWpTSF93WWNCRGM3ME5WSk0yLWdyY1JNaDU0ZnV5Y3dWSFpJMEpfYzhaOUY5N2RFek5QVVZUR1FqamFZWTVDSE5jM05ZbklsTHpmYV9LV3dRV0V2U2lkdk80UGhHTERFR2hvdjVjNnd0WjI1OUU4bzNIN2s4VFZOM0dlUE9ZdDk0dE…

Google News Wed, 19 Aug 2026

Centene(CNC.US) Officer Sells US$3.11 Million in Common Stock - Moomoo

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOTmF5NFcyZG1lc3hKd2lMbjROZG9xS1ZYLV9NSEZ2anNrZWNnR3pXRldyc3M4aEZHSzdlbGdDdmxRRkd4LW9BTTNwWWNsZ0RqX1JMc1R1UUFsR0drLXEwaU0wVjVKTXJWZ1FxbDlGbXNnSDBfWWhEWFJ2emt0TjctN21xTEl0VEJuMkdLbE…

Google News Wed, 02 Sep 2026

Why Centene Corporation (CNC) Stock Is Up Today - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQRm8zVVJVUGZUckIzZEt4UjMxOU8wTE13cEo1N1Y0M2RtZnFPbU9yWTZIVWlnZDhEdnl4V1FTSmgxejVDXzZCSGtmZHNad0ppQWdrVFBveG1UVE0tRGs0RUo3dzJoVXhPeG12UUkxMkFsTzFzQmR6b2ZlRXBDaDZTU0dZRWVQRnRvMi1MWQ…

Google News ue, 01 Sep 2026

Centene (CNC) Stock Still Looks Cheap After A 122% Run - simplywall.st

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQcTc1bUR0Wks4dzdaZUtKRUNkdGRvNHVIdU81MnBYakRfQWxRU3lVVHp4LW5tWnI5YTBUM1cxWUdYRUV3WVhuOWJtbVJOekN1MDc1eVVENUt5YnlHQUthOFdUWmVRcWdSVGo0aEhzVUpNU2dvYkp3ak9nbkk5aHpwY21jc0FwV3poUVZ0aG…

Google News Wed, 02 Sep 2026

Centene Stock Roars Back 117% in a Year: Is CNC Still a Buy? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNSWNRSWpXbjFHUURtNS1wRnZlT3gyeDlOOUJiNm5CRmhGWnVSUkEwbmJYUWxvVlROLWwtM0dhNU00ZUg0LXhHWUEyZmxUNHgzc1ZUcDBJWGFqQ1d3TDlPN2lZVzVKV21YSlBfNFBtTW5Pd1dSVUlEVEhFb1otWnQ4bHNvVXF4VXV0XzdrOW…

CNC — Frequently Asked Questions

What is the current share price of Centene Corporation (CNC)?

As of 2026-09-07 16:24 PDT, Centene Corporation (CNC) trades at $67.04 on NYSE. Its 52-week range is $26.93 to $68.72.

What is the market capitalisation of CNC?

Centene Corporation (CNC) has a market capitalisation of $33.12B on NYSE.

What is the P/E ratio of CNC?

CNC trades at a trailing price-to-earnings (P/E) ratio of -6.47. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.44.

What is the return on equity (ROE) of CNC?

CNC has a return on equity (ROE) of -20.36%. Its return on capital employed (ROCE) is -19.03%.

Is CNC a good stock to buy?

This page provides a data-driven analysis of Centene Corporation (CNC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Centene Corporation CNC SPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

symbol__ Stock Quote Price and Forecast - CNN

Is Centene (CNC) a Great Value Stock Right Now? - Yahoo Finance

Centene(CNC.US) Officer Sells US$3.11 Million in Common Stock - Moomoo

Why Centene Corporation (CNC) Stock Is Up Today - quiverquant.com

Centene (CNC) Stock Still Looks Cheap After A 122% Run - simplywall.st

Centene Stock Roars Back 117% in a Year: Is CNC Still a Buy? - Yahoo Finance

CNC — Frequently Asked Questions

What is the current share price of Centene Corporation (CNC)?

What is the market capitalisation of CNC?

What is the P/E ratio of CNC?

What is the return on equity (ROE) of CNC?

Is CNC a good stock to buy?

Explore More